Fluorescence-guided resection of gliomas

Søren Cortnum & René Johannes Laursen

ABSTRACT
INTRODUCTION: Malignant gliomas remain associated with a poor prognosis despite both surgical treatment and radiochemotherapy. Previous studies have shown that complete resection of contrast-enhancing tumours is achieved in less than 20-30% of patients. 5-aminolevulinic acid (5-ALA) is a pro-drug that leads to accumulation of fluorescent protoporphyrins in malignant gliomas. The fluorescence can be visualized intraoperatively by use of a modified microscope. The Department of Neurosurgery at Aalborg Hospital has recently adopted this new technique as the first centre in Denmark. Our preliminary results are presented as a retrospective case series.

MATERIAL AND METHODS: All patients who had undergone 5-ALA fluorescence-guided surgery due to suspected malignant glioma were included. Patients received a standard preoperative dose of Gliolan. All patients had a postoperative cerebral magnetic resonance imaging scan done within 72 hours to determine their postoperative resection status.

RESULTS: To date, 13 patients have undergone fluorescence-guided surgery. Total resection was achieved in 54-70% of the patients depending on the inclusion criteria. Total or near total resection was achieved in 92% of patients.

CONCLUSION: The small numbers in our case series do not allow for direct comparison to be made, but show that our results on postoperative resection status fall within the range reported in other studies on the efficacy of 5-ALA. The literature offers mounting evidence in support of the role of aggressive cytoreductive surgery in patients with malignant gliomas.

TRIAL REGISTRATION: not relevant.

FUNDING: not relevant.
Preoperative imaging studies were available on all patients. All patients had either a cerebral computed tomography (CT) or a cerebral magnetic resonance imaging (MRI) scan done. Patients received a standard preoperative dose of 1,500 mg Gliolan (Medac, Germany) dissolved into 50 ml of sterile water 2-4 hours prior to surgery (one vial of Gliolan contains 1,500 mg; issues of cost-effectiveness were discussed when choosing the standard dose). The recommended dose is 20 mg/kg. No patients received a dose that was larger than recommended. A blue-filter modified microscope for fluorescence-guided surgery was used in all cases (Zeiss-Pentero microscope).

During all operations, tissue samples were obtained for histopathological examination.

All patients had a postoperative cerebral MRI scan done within 72 hours to determine their postoperative resection status.

All patient data were reviewed retrospectively by two experienced members of the neurosurgical staff.

Both pre- and postoperative images were evaluated by both staff members. The consensual assessment was noted in the patient database.

Preoperative images were assessed with respect to the anatomical location of the tumour and whether the tumour was located in or in near proximity to eloquent cortical areas. Areas of motor- and language functions were considered eloquent areas. The visual cortex was not considered an eloquent area in this context as this location would have no or little impact on the preoperative surgical planning.

Preoperative images were also assessed as to whether the tumour was accessible to complete resection. To avoid biased opinions, the consensual assessment was noted before reviewing the postoperative images. Tumours crossing the midline and tumours with deep-seated locations involving the basal ganglia were considered inaccessible to complete resection. Tumours with ingrowth to the ventricles or multifocal locations were also considered inaccessible to complete resection.

The evaluation of the postoperative images was based on T1-weighted Fluid Attenuated Inversion Recovery (FLAIR) sequences before and after gadolinium contrast enhancement. If there was any doubt about the significance of a contrast-enhancing element, this was considered residual tumour. Three categories were applied: total resection, near-total resection (less than 5% residual tumour) and residual tumour.

All patient charts and results from histopathological examinations were reviewed. It was noted in the patient database if patients had any new persisting neurological deficits at the time of discharge.

RESULTS

To date, 13 patients have undergone fluorescence-guided surgery. These patients have all been included in this case series (see Table 1). Nine patients were male and four patients were female. Their median age was 63.5 years.

Judging from preoperative imaging, the tumour was located in non-eloquent areas in nine out of 13 patients and in close proximity to eloquent areas in the remaining four patients.

When reviewing all patient data, total resection had been achieved in seven out of 13 patients, which is equivalent to 54%.

In the original 5-ALA study by Stummer et al, 61% of patients received a total resection [10]. In that study, inclusion criteria dictated that distinct tumour characteristics were present on preoperative imaging, that the tumour was accessible to complete resection and that histopathology was diagnostic of malignant glioma.

If the same inclusion and exclusion criteria are applied to our patient data, patients number three and eight would be excluded as the tumour was not accessible to complete resection judging from the preoperative imaging. Patient number 13 would be excluded due to histological criteria and due to a somewhat unclear preoperative imaging suggestive of haemorrhage in a not clearly defined tumour.

If these criteria are applied, total resection would have been achieved in seven out of ten patients, which is equivalent to 70%.

As in the original 5-ALA study, the volume of the residual tumour was generally low in our series. Reviewing

---

**Table 1**

<table>
<thead>
<tr>
<th>Patient ID</th>
<th>Tumour location</th>
<th>Accessible to total resection?</th>
<th>Eloquent/ non-eloquent cortex</th>
<th>Total/near total residual tumour</th>
<th>Newly developed postoperative neurological deficits</th>
<th>Tumour histology</th>
</tr>
</thead>
<tbody>
<tr>
<td>1.</td>
<td>Frontal, left</td>
<td>Yes</td>
<td>Non-eloquent</td>
<td>Total</td>
<td>Yes</td>
<td>GBM</td>
</tr>
<tr>
<td>2.</td>
<td>Frontotemporal, left</td>
<td>Yes</td>
<td>Eloquent</td>
<td>Total</td>
<td>No</td>
<td>GBM</td>
</tr>
<tr>
<td>3.</td>
<td>Occipital, right, growth in ventricles</td>
<td>No</td>
<td>Non-eloquent</td>
<td>Near total</td>
<td>No</td>
<td>GBM</td>
</tr>
<tr>
<td>4.</td>
<td>Frontal, right</td>
<td>Yes</td>
<td>Non-eloquent</td>
<td>Total</td>
<td>No</td>
<td>GBM</td>
</tr>
<tr>
<td>5.</td>
<td>Occipital, right</td>
<td>Yes</td>
<td>Non-eloquent</td>
<td>Total</td>
<td>No</td>
<td>GBM</td>
</tr>
<tr>
<td>6.</td>
<td>Occipital, right</td>
<td>Yes</td>
<td>Non-eloquent</td>
<td>Total</td>
<td>No</td>
<td>GBM</td>
</tr>
<tr>
<td>7.</td>
<td>Frontal, right</td>
<td>Yes</td>
<td>Non-eloquent</td>
<td>Total</td>
<td>No</td>
<td>GBM</td>
</tr>
<tr>
<td>8.</td>
<td>Parietooccipital, left</td>
<td>No</td>
<td>Elloquent</td>
<td>Residual</td>
<td>No</td>
<td>GBM</td>
</tr>
<tr>
<td>9.</td>
<td>Temporal, left</td>
<td>Yes</td>
<td>Non-eloquent</td>
<td>Total</td>
<td>No</td>
<td>GBM</td>
</tr>
<tr>
<td>10.</td>
<td>Parietal, left</td>
<td>Yes</td>
<td>Elloquent</td>
<td>Total</td>
<td>Yes</td>
<td>GBM</td>
</tr>
<tr>
<td>11.</td>
<td>Temporoparietal, left</td>
<td>Yes</td>
<td>Elloquent</td>
<td>Total</td>
<td>Yes</td>
<td>GBM</td>
</tr>
<tr>
<td>12.</td>
<td>Temporal, left</td>
<td>Yes</td>
<td>Non-eloquent</td>
<td>Near total</td>
<td>No</td>
<td>GBM</td>
</tr>
<tr>
<td>13.</td>
<td>Frontal, left, tumour with haemorrhage</td>
<td>Yes</td>
<td>Non-eloquent</td>
<td>Near total</td>
<td>No</td>
<td>PNET</td>
</tr>
</tbody>
</table>
the complete dataset, total or near-total resection was achieved in 12 out of 13 patients, which is equivalent to 92%. As mentioned above, the tumour was located in close relation to eloquent cortical areas in four out of 13 patients and in non-eloquent areas in the remaining nine patients.

In a single patient whose tumour was located in a non-eloquent area, new neurological deficits were observed postoperatively. This patient had developed a paresis of the right lower extremity. On postoperative imaging, signs of fresh ischaemia were noted in the distribution area of the pericallosal artery. The newly developed neurological deficits were attributed to accidental closure of this artery. This is seen as a complication of a general nature and should not be attributed to an extended fluorescence-guided resection per se.

Postoperative neurological worsening was observed in two patients whose tumours were located in eloquent areas. One patient experienced a worsening of pre-existing aphasia and a newly developed slight right-sided hemiparesis. The second patient experienced worsening of a pre-existing aphasia.

Histopathological examinations resulted in a definitive diagnosis of glioblastoma multiforme (GBM) in 12 out of 13 patients. The last patient was diagnosed with a primitive neuroectodermal tumour (PNET), which was described as a ganglio-neuroblastoma grade IV with some differentiation approximating a glioblastoma.

In all patients, the tumour exhibited usable fluorescence during surgery.

No toxic side-effects were observed among the patients in this case-series.

DISCUSSION
In conclusion, total resection was achieved in 54-70% of patients depending on the inclusion and exclusion criteria deployed. The patient numbers are too small to make any direct comparison with the original 5-ALA study by Stummer et al [14] with regard to postoperative resection status.

Histopathological examination results in a definitive diagnosis of glioblastoma multiforme (GBM) in 12 out of 13 patients. The last patient was diagnosed with a primitive neuroectodermal tumour (PNET), which was described as a ganglio-neuroblastoma grade IV with some differentiation approximating a glioblastoma.

In all patients, the tumour exhibited usable fluorescence during surgery.

No toxic side-effects were observed among the patients in this case-series.

CONCLUSION
Total resection was achieved in 54-70% of patients depending on the inclusion criteria used. Total or near-total resection was achieved in 92% of patients.

The small numbers in our case-series do not allow direct comparisons to be made, but show that our results fall in the same range as reported in the original 5-ALA study by Stummer et al [14] with regard to postoperative resection status.

The literature offers mounting evidence in support of the role of aggressive cytoreductive surgery in patients with newly diagnosed malignant gliomas.

Several studies also suggest a synergistic effect between aggressive cytoreductive surgery and radiochemotherapy.

CORRESPONDENCE: Søren Cortnum, Ny Kastelvej 32, 15., 9000 Aalborg, Denmark. E-mail: cortnum@hotmail.com
ACCEPTED: 24 April 2012
CONFLICTS OF INTEREST: none

LITERATURE